Abstract
Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. SLN are defined as aqueous colloidal carrier systems in the size range of 50-1000nm made up of solid lipid matrix. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. They exhibit major advantages such as modulated release, improved bioavailability, protection of chemically labile molecules, cost effective excipients, improved drug incorporation and wide application spectrum. As a novel type of lipid nanoparticles with solid matrix, the nanostructured lipid carriers (NLC) are presented which overcomes the problems associated with SLN such as expulsion of drug from the matrix over the period of time. This paper presents an overview about the selection of the ingredients, different ways of production, drug incorporation and release, characterization of quality and structure, sterilization, storage, stability and applications of SLN & NLC dispersions.
Keywords: Poor solubility, bioavailability, solid lipid nanoparticles, nanostructured lipid carriers, characterization, stability, cholesterol, lipid dispersion, cold homogenization techniques, Triglycerides
Current Drug Therapy
Title: Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review
Volume: 6 Issue: 4
Author(s): Rajashree Hirlekar, Harshal Garse and Vilasrao Kadam
Affiliation:
Keywords: Poor solubility, bioavailability, solid lipid nanoparticles, nanostructured lipid carriers, characterization, stability, cholesterol, lipid dispersion, cold homogenization techniques, Triglycerides
Abstract: Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. SLN are defined as aqueous colloidal carrier systems in the size range of 50-1000nm made up of solid lipid matrix. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. They exhibit major advantages such as modulated release, improved bioavailability, protection of chemically labile molecules, cost effective excipients, improved drug incorporation and wide application spectrum. As a novel type of lipid nanoparticles with solid matrix, the nanostructured lipid carriers (NLC) are presented which overcomes the problems associated with SLN such as expulsion of drug from the matrix over the period of time. This paper presents an overview about the selection of the ingredients, different ways of production, drug incorporation and release, characterization of quality and structure, sterilization, storage, stability and applications of SLN & NLC dispersions.
Export Options
About this article
Cite this article as:
Hirlekar Rajashree, Garse Harshal and Kadam Vilasrao, Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review, Current Drug Therapy 2011; 6 (4) . https://dx.doi.org/10.2174/157488511798109637
DOI https://dx.doi.org/10.2174/157488511798109637 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets <i>In Silico</i> Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain
Current Drug Discovery Technologies Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Expression of Angiogenesis-related Genes in a Group of Iranian Cases of Breast Cancer
Current Pharmacogenomics and Personalized Medicine Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Subject Index To Volume 9
Combinatorial Chemistry & High Throughput Screening Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry Performance of Green Desymmetrization Methods toward Bioactive Cephalostatin Analogues
Current Medicinal Chemistry Synthesis and Anticancer Activity of Some 1H-inden-1-one Substituted (Heteroaryl)Acetamide Derivatives
Letters in Drug Design & Discovery Identifying Functional Modules Using Energy Minimization with Graph Cuts
Current Bioinformatics Kinetic Measurement Techniques in the Evaluation of Lipid Metabolism
Current Drug Discovery Technologies Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Use of Fullerenes in Cosmetics
Recent Patents on Biotechnology Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects
Current Medicinal Chemistry Design, Synthesis and Biological Activity of New Hydroxamic Acids Containing 2-Imidazolylphenyl(oxy/thio)alkanoic Fragment
Current Bioactive Compounds Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections
Current Molecular Medicine